SOHO 2026 | NGS-MRD assessment and targeted treatment selection in ALL
Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, discusses the potential of next-generation sequencing (NGS)-based measurable residual disease (MRD) assessment in acute lymphoblastic leukemia (ALL). Prof. Ribera highlights that combining NGS-MRD assessment with the genetic basis of the disease may help guide treatment selection and support the use of targeted therapies in specific ALL subtypes. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Now, we are improving our methods of MRD detection in either Ph-positive ALL, Ph-negative ALL, even T-ALL, and I think that at the end, the NGS will be the method of choice of MRD assessment. So, keeping this in mind, we can split our therapies according to the MRD, NGS-based MRD, and the genetic basis of the disease in order to include targeted therapies. For example, TKI such as blina for Ph-positive ALL, or for example in KMT2A B-cell precursor ALL to include many inhibitors combined with chemotherapy...
Now, we are improving our methods of MRD detection in either Ph-positive ALL, Ph-negative ALL, even T-ALL, and I think that at the end, the NGS will be the method of choice of MRD assessment. So, keeping this in mind, we can split our therapies according to the MRD, NGS-based MRD, and the genetic basis of the disease in order to include targeted therapies. For example, TKI such as blina for Ph-positive ALL, or for example in KMT2A B-cell precursor ALL to include many inhibitors combined with chemotherapy. For T-ALL up to now we don’t have targeted therapies but for relapsed/refractory patients new CAR-T will be a treatment of choice. So the combination of genetics and well-performed MRD assessment will open our window to treat more specifically the subtypes of ALL.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
